The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in ...

Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from ...

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...

The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

In this video, Ann S. LaCasce, MD, MMSc, highlights preliminary results of a study of a chemotherapy-light triple combination regimen in older patients with diffuse large B-cell lymphoma.

The Food and Drug Administration (FDA) has approved updated labeling for Unloxcyt ™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally ...